Immunomodulatory Therapy Does Not Increase the Risk of Cancer in Persons With Inflammatory Bowel Disease and a History of Extracolonic Cancers.

Related Articles Immunomodulatory Therapy Does Not Increase the Risk of Cancer in Persons With Inflammatory Bowel Disease and a History of Extracolonic Cancers. Am J Gastroenterol. 2019 May;114(5):771-776 Authors: Mañosa M, Chaparro M, Juan A, Aràjol C, Alfaro I, Mínguez M, Velayos B, Benítez JM, Mesonero F, Sicilia B, Zabana Y, Villoria A, Gisbert JP, Domènech E, ENEIDA registry by GETECCU Abstract OBJECTIVES: Immunosuppressant therapies (IMTs; thiopurines, anti-tumor necrosis factor agents) may influence the immunologic control of cancer and might facilitate the spread and recurrence of cancer. This study assesses…

Read More

Serum Protein Biomarkers of Fibrosis Aid in Risk Stratification of Future Stricturing Complications in Pediatric Crohn’s Disease.

Serum Protein Biomarkers of Fibrosis Aid in Risk Stratification of Future Stricturing Complications in Pediatric Crohn’s Disease. Am J Gastroenterol. 2019 May;114(5):777-785 Authors: Wu J, Lubman DM, Kugathasan S, Denson LA, Hyams JS, Dubinsky MC, Griffiths AM, Baldassano RN, Noe JD, Rabizadeh S, Gulati AS, Rosh JR, Crandall WV, Higgins PDR, Stidham RW Abstract OBJECTIVES: Avoiding fibrostenotic complications is of paramount concern in the management of Crohn’s disease (CD). We sought to investigate the association of candidate biomarkers of fibrosis collected at diagnosis with the future development of fibrostenotic CD.…

Read More

Correction: No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials.

Correction: No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. Am J Gastroenterol. 2019 Apr 29;: Authors: Singh S, Proudfoot J, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ PMID: 31033520 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31033520?dopt=Abstract

Read More

Histologic Remission in Ulcerative Colitis: Are We There Yet?

Histologic Remission in Ulcerative Colitis: Are We There Yet? Am J Gastroenterol. 2019 Apr 22;: Authors: Long MD, Rubin DT Abstract As the field of inflammatory bowel disease moves toward treating to a “target” that includes mucosal healing, better outcome definitions are needed. One important question is whether the definition of mucosal healing should include “histologic” remission. In this systematic review and meta-analysis, the authors describe histologic healing rates of medical therapies for ulcerative colitis in randomized controlled trials. Although observational data demonstrate that histologic remission has consistently been associated…

Read More

Inflammatory Bowel Disease: A Practical Path to Transitioning From Pediatric to Adult Care.

Inflammatory Bowel Disease: A Practical Path to Transitioning From Pediatric to Adult Care. Am J Gastroenterol. 2019 Apr 12;: Authors: Menon T, Afzali A Abstract The growing need for transitional care is quickly becoming apparent in the medical community because children with chronic illnesses are surviving into adulthood. Transitional care is the coordinated movement of young adults with chronic conditions from the pediatric to adult health care setting. This transition period is associated with poorer health outcomes due to differences in pediatric and adult health care models, reluctance to change…

Read More

Manipulation of the Gut-Liver Axis Using Microbiome Restoration Therapy in Primary Sclerosing Cholangitis.

Manipulation of the Gut-Liver Axis Using Microbiome Restoration Therapy in Primary Sclerosing Cholangitis. Am J Gastroenterol. 2019 Mar 12;: Authors: Bajaj JS, Hays RA Abstract Alteration of the normal gut-liver axis is important in primary sclerosing cholangitis (PSC). Lack of effective medical therapy for PSC makes microbiome restoration an alluring therapeutic target. Allegretti et al. performed an open-label safety trial of fecal microbiota transplant (FMT) in noncirrhotic PSC patients with inflammatory bowel disease in remission on minimal therapy. FMT was safe in this population, and after FMT, there was a…

Read More

Exposure to Vedolizumab in IBD Pregnant Women Appears of Low Risk for Mother and Neonate: A First Prospective Comparison Study.

Exposure to Vedolizumab in IBD Pregnant Women Appears of Low Risk for Mother and Neonate: A First Prospective Comparison Study. Am J Gastroenterol. 2019 Mar 05;: Authors: Bar-Gil Shitrit A, Ben Yaʼacov A, Livovsky DM, Cuker T, Farkash R, Hoyda A, Granot T, Avni-Biron I, Lahat A, Goldin E, Grisaru-Granovsky S Abstract OBJECTIVES: Despite encouraging data gathered in inflammatory bowel diseases (IBD) patients, Vedolizumabs’ (VDZ) safety profile in pregnancy is not established. DESIGN: Data of 330 consecutive pregnancies with IBD was prospectively collected. RESULTS: Women with IBD were treated with:…

Read More

A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review.

A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. Am J Gastroenterol. 2019 Mar 22;: Authors: Ungaro R, Colombel JF, Lissoos T, Peyrin-Biroulet L Abstract OBJECTIVES: In 2015, the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program proposed shifting the therapeutic focus on ulcerative colitis (UC) toward altering the natural history of the disease course by regularly monitoring objective measurements of disease activity and tailoring treatment accordingly. The therapeutic paradigm shift was well received in the research community and is often cited. However, new evidence on optimal UC treatment…

Read More

The Efficacy of Split-Dose Bowel Preparations for Polyp Detection: A Systematic Review and Meta-Analysis.

The Efficacy of Split-Dose Bowel Preparations for Polyp Detection: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2019 Mar 11;: Authors: Zawaly K, Rumbolt C, Abou-Setta AM, Neilson C, Rabbani R, Zarychanski R, Singh H Abstract INTRODUCTION: Split-dose bowel preparation leads to superior colon cleansing for colonoscopy. However, the magnitude of benefit in detecting colonic polyps is uncertain. We performed a systematic review to synthesize the data on whether using a split-dose bowel preparation regimen improves the detection of polyps when compared with other dosing methods or regimen products. METHODS:…

Read More

Impact of Obesity on Disease Activity and Patient-Reported Outcomes Measurement Information System (PROMIS) in Inflammatory Bowel Diseases.

Impact of Obesity on Disease Activity and Patient-Reported Outcomes Measurement Information System (PROMIS) in Inflammatory Bowel Diseases. Am J Gastroenterol. 2019 Mar 11;: Authors: Jain A, Nguyen NH, Proudfoot JA, Martin CF, Sandborn WJ, Kappelman MD, Long MD, Singh S Abstract INTRODUCTION: We conducted a cohort study on the impact of obesity on disease activity and Patient-Reported Outcomes Measurement Information System (PROMIS) measures in the inflammatory bowel disease (IBD) Partners cohort. METHODS: We performed a cross-sectional and longitudinal study within IBD Partners, an internet-based cohort of >15,000 patients living with…

Read More
<< Go Back